Welcome to the e-CCO Library!

P544: Impact of patient education on switch acceptance in IBD patients in remission, with infliximab originator switched for an infliximab biosimilar: a prospective study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Hastier-De Chelle*1, V. Cluzeau1, J. Condat1, N. Arab1, X. Hébuterne1, J. Filippi1

Created: Friday, 22 February 2019, 9:41 AM
P544: Low TNF production and low TREM1 expression as negative predictors for remission under adalimumab therapy in Crohn´s Disease patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Jessen, B.(1);Tóth, M.(1)*;Freise, I.(1);Staudacher, J.(1);Haag, L.M.(1);Kredel, L.(1);Schumann, M.(1);Weidinger, C.(1);Sonnenberg, E.(1);Siegmund, B.(1);
Created: Friday, 14 July 2023, 11:05 AM
P544: Patients with moderate to severe Crohn’s disease with and without prior biologic failure demonstrated improved clinical outcomes with risankizumab: Results from phase 3 induction and maintenance trials
Year: 2022
Source: ECCO'22
Authors: D'Haens, G.(1);Beaton, M.(2);Bossuyt, P.(3);Dotan, I.(4);Sands, B.(5);Sugimoto, K.(6);Neimark, E.(7);Song, A.(8);Wallace, K.(8);Zhou, Q.(9);Kligys, K.(10);Ferrante, M.(11);
Created: Friday, 11 February 2022, 3:56 PM
P544: Point-of-care finger prick test for C-reactive protein, infliximab and adalimumab serum concentrations
Year: 2021
Source: ECCO'21 Virtual
Authors: Volkers, A.(1);Löwenberg, M.(1);Bray, K.(2);Bahur, B.(2);Braad, M.(1);Abeling, Y.(1);Gecse, K.(1);Duijvestein, M.(1);Ponsioen, C.(1);D'Haens, G.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P545 Deep remission assessed by endoscopy, magnetic resonance or intestinal ultrasound, in refractory Crohn’s disease patients in clinical remission with ustekinumab: a real-life single-centre experience
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M.I. Calvo Moya1, I. Omella Usieto1, Y. González Lama1, V. Matallana Royo1, I. González Partida1, B. Menchen Viso2, R. De Lucas Téllez de Meneses1, M. González Rodriguez1, P. Bella del Castillo1, M.I. Vera Mendoza1

Created: Thursday, 30 January 2020, 10:12 AM
P545: Antigenic response to CT-P13 and remicade in inflammatory bowel disease patients shows similar epitope recognition
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Goncalves1*, M. Santos1, R. Acurcio1, I. Iria1, L. Gouveia1, P. Brito1, A.C. Cunha Santos1, A. Barbas2,3, J. Galvão2, I. Barbosa2, F. Aires da Silva4, A. Alcobia5, M. Cavaco6, M. Cardoso1, J. Delgado Alves7,8, J. Carey9, T. Dorner10, J. Eurico Fonseca6,11, C. Palmela12, J. Torres12, C. Lima Vieira13, D. Trabuco13, G. Fiorino14, A. Strik15, M. Yavzori16, I. Rosa17, L. Correia18, F. Magro19, G. D'Haens15, S. Ben-Horin16, P. Lakatos20,21, S. Danese14

Created: Thursday, 21 February 2019, 9:14 AM
P545: Calprotectin at week 12 is a predictor for histological remission in ulcerative colitis patients treated with Vedolizumab
Year: 2021
Source: ECCO'21 Virtual
Authors: Rubstov, D.(1);Kakkadasam Ramaswamy, P.(1);Edwards, J.(1);Shukla, D.(1);Willmann, L.(1);Moattar, H.(1);Bhullar, M.(1);Ishaq, N.(1);Dorrington, A.(1);Mohsen, W.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P545: Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients in clinical remission: preliminary results
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Guerrero Puente L.N.*1, Iglesias Flores E.1, Benítez Cantero J.M.1, Cárdenas Aranzana M.J.2, Medina Medina R.1, Salgueiro Rodríguez I.1, Aguilar Melero P.1, Manzanares Martin B.3, García-Sánchez V.1

Created: Wednesday, 20 February 2019, 10:36 AM
P545: Does gender matter? Gender-related nutritional behaviour, disease activity and quality of life in patients with inflammatory bowel diseases
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Pueschel, L.(1);Kockelmann, F.(2);Kueck, M.(3);Tegtbur, U.(3);Seidler, U.(1);Lenzen, H.(1);Attaran-Bandarabadi, M.(4);Bachmann, O.(5);Wedemeyer, H.(1);Wiestler, M.(1)*;
Created: Friday, 14 July 2023, 11:05 AM
P545: Elderly patients with inflammatory bowel disease (IBD) are less likely to persist on anti-TNF therapy compared with younger patients: data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Porcari1, O. Fidanza1, A. Alibrandi2, S. Renna3, M. Cappello4, S. Siringo5, A. Privitera6, G. Inserra7, F. Mocciaro8, G. Magri9, A. Carroccio10, N. Belluardo11, C. Bertolami12, S. Garufi13, M. Ventimiglia3, F. Macaluso3, A. Viola1, M. Cottone15, A. Orlando3, W. Fries*16

Created: Friday, 22 February 2019, 9:41 AM
P545: Safety of ustekinumab in pregnant patients with inflammatory bowel disease and in their offspring: results from the DUMBO registry of GETECCU
Year: 2022
Source: ECCO'22
Authors: Chaparro, M.(1);Gutiérrez, A.(2);Calviño-Suárez, C.(3); Huguet, J.M.(4);Calvo, M.(5);Aguas, M.(6);Camargo Camero, R.(7);de Jorge Turrión, M.Á.(8);Hervías Cruz, D.(9);López Serrano, P.(10);Marín Pedrosa, S.(11);Martínez Montiel, P.(12);Rivero, M.(13);Vicente Lidón, R.(14);Arias García, L.(15);Arroyo, M.(16);Bujanda, L.(17); Casanova, M.J.(1);Figueiras, M.(18);Lucendo, A.J.(19);Manceñido Marcos, N.(20);Márquez, L.(21);Martín-Arranz, M.D.(22);Boscá Watts, M.(23);Ber, Y.(24);Ramírez de la Piscina Urraca, P.(25);Pérez-Martínez, I.(26);Robles, V.(27);Ruiz-Cerulla, A.(28);Vázquez Morón, J.M.(29);Madero, L.(2);Barreiro-de Acosta, M.(3);Capilla, M.(4);Vera Mendoza, I.(5);Acosta, D.(1);Brenes, Y.(1);Hermida, S.(1);Parra, P.(1);G. Donday, M.(1); Gisbert, J.P.(1);
Created: Friday, 11 February 2022, 3:56 PM
P546 Ileal ulcer size significantly impacts the ability to achieve endoscopic remission: a post-hoc analysis from the SONIC trial
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N. Narula1, E. Wong1, A. Achuthan1, P. Dulai2, J.F. Colombel3, J.K. Marshall1, M. Ferrante4, W. Reinisch5

Created: Thursday, 30 January 2020, 10:12 AM
P546: Comparative efficacy and safety of upadacitinib versus ustekinumab as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Reinisch, W.(1)*;Panaccione, R.(2);Duijvestein, M.(3);Ceballos Santos, D.(4);Melmed, G.Y.(5);Xuan, S.(6);Wegrzyn, L.(6);Levy, G.(6);Ilo, D.(6);Sanchez Gonzalez, Y.(6);
Created: Friday, 14 July 2023, 11:05 AM
P546: Minimal risk of lymphoma despite long term use of azathioprine in patients with Inflammatory Bowel Disease: a longitudinal cohort analysis from Northern India.
Year: 2022
Source: ECCO'22
Authors: Ranjan, M.K.(1);Kante, B.(1);Vuyyuru, S.K.(1);Kumar, P.(1);Mundhra, S.K.(1);Golla, R.(1);Sharma, R.(2);Das, P.(3);Sahni, P.(4);Makharia, G.(1);Kedia, S.(1);Ahuja, V.(1);
Created: Friday, 11 February 2022, 3:56 PM
P546: The safety and efficacy of the new-generation budesonide-MMX in the aspect of the cytochrome P-450 enzyme genotype
Year: 2021
Source: ECCO'21 Virtual
Authors: Resál, T.(1);Farkas, K.(1);Molnár, T.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P546: Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Torres1, D. Martín Arranz2, M. Sánchez Azofra2, E. Martín Arranz2, L. Garcia2, P. Nozal3, J. Pascual1, I. Apraiz1, M. López1, D. Arteta1, D. Nagore*1

Created: Friday, 22 February 2019, 9:41 AM
P546: Vedolizumab outcomes in real-world bio-naive ulcerative colitis and Crohn’s disease patients (EVOLVE) in Canada: Interim results
Year: 2018
Source: ECCO '18 Vienna
Authors:

B. Bressler1*, A.-J. Greenup1, M. Bassel2, D. Stein3, M. Soni3, G. Radulescu4, C. Neish4, J.M. Khalid5, D. Demuth5

Created: Thursday, 21 February 2019, 9:14 AM
P546: Which are the optimal adalimumab trough levels associated with biological remission in patients with inflammatory bowel disease?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Serra K.*1, Rodríguez-Alonso L.1, Padullés N.2, Rodríguez-Moranta F.1, Arajol C.1, Gilabert P.1, Rodríguez R.1, Bas J.3, Morandeira-Rego F.3, Santacana E.2, Padullés A.2, Guardiola J.1

Created: Wednesday, 20 February 2019, 10:36 AM
P547 Inadequate vitamin C status and association with inflammatory biomarkers in adults with active Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Wall1, K. MacFarlane2, A. Carr3, A. Day4, R. Gearry1

Created: Thursday, 30 January 2020, 10:12 AM
P547: Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with ulcerative colitis (SVEAH UC)
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Eriksson1, S. Rundquist1*, V. Lykiardopoulos2, P. Karlén3, O. Grip4, C. Söderman5, S. Almer6, E. Hertervig7, J. Gunnarsson8, C. Malmgren9, J. Delin10, H. Strid11, M. Sjöberg12, D. Öberg13, D. Bergemalm1, R. Udumyan14, H. Hjortswang2, The SWIBREG SVEAH Study Group, J. Halfvarson1

Created: Thursday, 21 February 2019, 9:14 AM